TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price was up 1.4% during trading on Tuesday . The stock traded as high as $2.86 and last traded at $2.81. Approximately 158,324 shares were traded during mid-day trading, a decline of 100% from the average session volume of 32,220,806 shares. The stock had previously closed at $2.77.
TNF Pharmaceuticals Price Performance
The company has a market capitalization of $4.97 million, a price-to-earnings ratio of -0.01 and a beta of 2.04. The stock has a 50 day simple moving average of $3.40 and a two-hundred day simple moving average of $3.69.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Further Reading
- Five stocks we like better than TNF Pharmaceuticals
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
- Sociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the Show
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
